Celgene (CELG) merged with Bristol-Myers Squibb Co. (BMY) in a cash and stock merger. Celgene shareholders will receive 1 share of BMY for each share of CELG previously held and $50 cash per share of CELG previosuly held.
If you have questions regarding corporate actions that affect shares you’re holding, we recommend contacting the appropriate company’s Investor Relations team, or locating the Investor Relations page on their website for clarification. Investing involves risk; you may lose money. Brokerage services provided by Cash App Investing LLC, member FINRA/SIPC and a subsidiary of Square, Inc. Past performance of a security or financial product does not guarantee future results or returns. You should consider the risks before investing. For more on the risks of investing see our Disclosure Library."